Edition:
United Kingdom

Income Statements: Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

3.27USD
13 Sep 2019
Change (% chg)

$0.11 (+3.48%)
Prev Close
$3.16
Open
$3.23
Day's High
$3.33
Day's Low
$3.18
Volume
20,580
Avg. Vol
67,880
52-wk High
$32.40
52-wk Low
$1.88

Interim Income Statement
View: AnnualInterim

In Millions ofU.S. Dollars
(except for per share items)
2019
2019-06-30
Period Length
3 Months
Revenue --
Other Revenue, Total --
Total Revenue 0.0
Cost of Revenue, Total --
Gross Profit --
Selling/General/Admin. Expenses, Total 6.9
Research & Development 4.2
Depreciation/Amortization --
Interest Expense, Net - Operating --
Interest/Investment Income - Operating --
Interest Expense(Income) - Net Operating --
Unusual Expense (Income) --
Other Operating Expenses, Total --
Total Operating Expense 11.2
Operating Income (11.2)
Interest Expense, Net Non-Operating --
Interest/Invest Income - Non-Operating 0.1
Interest Income(Exp), Net Non-Operating --
Gain (Loss) on Sale of Assets --
Other, Net --
Net Income Before Taxes (11.0)
Provision for Income Taxes --
Net Income After Taxes (11.0)
Minority Interest --
Equity In Affiliates --
U.S. GAAP Adjustment --
Net Income Before Extra. Items (11.0)
Accounting Change --
Discontinued Operations --
Extraordinary Item --
Tax on Extraordinary Items --
Net Income (11.0)
Preferred Dividends --
General Partners' Distributions --
Miscellaneous Earnings Adjustment --
Pro Forma Adjustment --
Interest Adjustment - Primary EPS --
Income Available to Com Excl ExtraOrd (11.0)
Income Available to Com Incl ExtraOrd (11.0)
Basic Weighted Average Shares 10.09
Basic EPS Excluding Extraordinary Items (1.094)
Basic EPS Including Extraordinary Items (1.094)
Dilution Adjustment --
Diluted Weighted Average Shares 10.09
Diluted EPS Excluding ExtraOrd Items (1.094)
Diluted EPS Including ExtraOrd Items (1.094)
DPS - Common Stock Primary Issue 0.000
Gross Dividends - Common Stock 0.0
Total Special Items --
Normalized Income Before Taxes (11.0)
Effect of Special Items on Income Taxes --
Inc Tax Ex Impact of Sp Items --
Normalized Income After Taxes (11.0)
Normalized Inc. Avail to Com. (11.0)
Basic Normalized EPS (1.094)
Diluted Normalized EPS (1.094)

UPDATE 2-FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

June 25Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.